3 Important Catalysts That Fueled Repligen in 2013
Repligen may work behind the scenes to power the biotech industry, but these three events catalyzed the bioprocess company itself in the past 12 months.
Gilead's Sofosbuvir Gets New Name, Price, Headaches
The highly regarded hepatitis C treatment is set to hit markets, but insurers may find its price too big a pill to swallow.
Eli Lilly Struggles for Pipeline Success
Edivoxetine failure dampens Lilly's R&D efforts
Iclusig Troubles Continue for Ariad in Europe
Ariad's leukemia agent struggles with European regulators after the FDA pulled its product.